# RegCell Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/regcell-co

- Industry: Biotechnology
- Headquarters: Emeryville, US
- Website: www.regcell.jp
- Total disclosed funding: $63M
- Latest round: Series A (Sep 16, 2026)
- Investors on record: 19

## About

Based in Japan, RegCell, Inc. focuses on innovative immune system control technologies, specifically the development and application of regulatory T cells (Tregs) for therapeutic solutions in various medical conditions. RegCell, Inc., founded in 2016, specializes in immune system control technologies. In September 2026, RegCell Co., Ltd. raised USD 44 million in series A funding led by Playground Global, LLC, with participation from Global Brain, Mitsui Chemicals, LG Technology Ventures, Alumni Ventures Group, Medical Incubator Japan, Fast Track Initiative, University of Tokyo Edge Capital Partners, Osaka University Venture Capital, and Kyoto University Innovation Capital.

RegCell, Inc. specializes in innovative immune system control technologies through the development and application of regulatory T cells (Tregs). Their offerings focus on advanced therapeutic solutions aimed at modulating immune responses in conditions such as autoimmune diseases, cancer, and transplant rejection. The company targets healthcare providers, research institutions, and pharmaceutical companies across Japan, the United States, and Europe, aiming to improve patient outcomes in immunological scenarios.

RegCell, Inc. generates revenue through direct sales and partnerships with healthcare organizations and research institutions that utilize their Treg-based therapies. Revenue is derived from agreements with hospitals and clinics, where RegCell's products are integrated into treatment regimens or clinical trials. The company may also engage in collaborations with pharmaceutical firms for the co-development of specialized therapies, aligning with premium pricing strategies typically seen in the biopharmaceutical sector.

The company plans to use the September 2026 funding to support the development of autoimmune disease treatments.

## Funding rounds

- Series A, Sep 16, 2026, $44M — University of Tokyo Edge Capital Partners, Global Brain, Alumni Ventures Group, Mitsui Chemicals, Playground Global, LLC, OSAKA University Venture Capital, Fast Track Initiative, Kyoto University Innovation Capital, LG Technology Ventures, Medical Incubator Japan
- Seed, Mar 18, 2025, $8.5M — University of Tokyo Edge Capital Partners, Mitsubishi UFJ Capital, Osaka University Venture Capital, Fast Track Initiative, Kyoto University Innovation Capital, Celadon Partners
- Series C, Apr 26, 2022, $4.2M — University of Tokyo Edge Capital Partners, Osaka University Venture Capital
- Series B, Aug 4, 2017, $5.8M — Nissay Capital, Fujifilm Holdings Corporation, MIRAIDOOR, Japan Science and Technology Agency, Chushin Venture Capital, Kagawa Securities, SCREEN Holdings Co., Ltd.

## Investors

- Nissay Capital (https://capitalatlas.ai/funds/nissay-capital) — Series B
- Fujifilm Holdings Corporation — Series B
- MIRAIDOOR (https://capitalatlas.ai/funds/miraidoor) — Series B
- Japan Science and Technology Agency — Series B
- Chushin Venture Capital (https://capitalatlas.ai/funds/chushin-venture-capital) — Series B
- Kagawa Securities — Series B
- SCREEN Holdings Co., Ltd. — Series B
- University of Tokyo Edge Capital Partners (https://capitalatlas.ai/funds/university-of-tokyo-edge-capital-partners) — Series C, Seed, Series A
- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series C, Seed, Series A
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Seed
- Fast Track Initiative (https://capitalatlas.ai/funds/fast-track-initiative) — Seed, Series A
- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Seed, Series A
- Celadon Partners (https://capitalatlas.ai/funds/celadon-partners) — Seed
- Global Brain (https://capitalatlas.ai/funds/global-brain) — Series A
- Alumni Ventures Group (https://capitalatlas.ai/funds/alumni-ventures-group) — Series A
- Mitsui Chemicals — Series A
- Playground Global, LLC — Series A
- LG Technology Ventures (https://capitalatlas.ai/funds/lg-technology-ventures) — Series A
- Medical Incubator Japan (https://capitalatlas.ai/funds/medical-incubator-japan) — Series A